These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15729422)

  • 1. Painful legs, aching heart: Reducing cardiovascular risk in patients with peripheral arterial disease with angiotensin-converting enzyme inhibition.
    Gupta MK; Verma S
    Can J Cardiol; 2005 Feb; 21(2):194-5. PubMed ID: 15729422
    [No Abstract]   [Full Text] [Related]  

  • 2. Should all patients with peripheral arterial disease be treated with an angiotensin-converting enzyme inhibitor?
    Al-Omran M; Lindsay TF
    Can J Cardiol; 2005 Feb; 21(2):189-93. PubMed ID: 15729421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Secondary medical prevention in patients with peripheral arterial disease.
    Schouten O; Welten GM; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
    [No Abstract]   [Full Text] [Related]  

  • 7. Should angiotensin-converting enzyme inhibitors be used in all patients with coronary artery disease or restricted to those with a history of myocardial infarction or myocardial revascularization?
    Danchin N
    Arch Cardiovasc Dis; 2009 Feb; 102(2):81-3. PubMed ID: 19303573
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.
    Anselmino M; Malmberg K; Ohrvik J; Rydén L;
    Eur J Cardiovasc Prev Rehabil; 2008 Apr; 15(2):216-23. PubMed ID: 18391651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of hypertension in patients with peripheral artery disease.
    Clement DL
    Blood Press; 2006; 15(4):251-2. PubMed ID: 17078187
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of risk in peripheral artery disease: recent therapeutic advances.
    Hackam DG; Goodman SG; Anand SS
    Am Heart J; 2005 Jul; 150(1):35-40. PubMed ID: 16084148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
    Costanzo P; Perrone-Filardi P; Petretta M; Marciano C; Vassallo E; Gargiulo P; Paolillo S; Petretta A; Chiariello M
    J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
    Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of angiotensin-converting enzyme inhibitors in patients undergoing coronary artery bypass graft surgery.
    Lazar HL
    Vascul Pharmacol; 2005 Feb; 42(3):119-23. PubMed ID: 15792929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.
    Papademetriou V
    Am Heart J; 2009 Jun; 157(6 Suppl):S24-30. PubMed ID: 19450721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A safe new dose of heart protection. Study shows drug can prevent attacks, strokes.
    Comarow A
    US News World Rep; 1999 Nov; 127(20):76. PubMed ID: 10623306
    [No Abstract]   [Full Text] [Related]  

  • 18. Peripheral arterial disease: a review of disease awareness and management.
    Watson K; Watson BD; Pater KS
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):365-79. PubMed ID: 17296541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
    Asselbergs FW; van Gilst WH
    Curr Opin Cardiol; 2007 Jul; 22(4):267-72. PubMed ID: 17556876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected.
    Paraskevas KI; Giannoukas AD; Mikhailidis DP
    Ann Vasc Surg; 2009; 23(5):690-9. PubMed ID: 19747617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.